Yes, coadministration of influenza and RSV vaccines at the same visit is acceptable. Evidence is limited and mixed concerning the effects of coadministration on antibody titers or on any increase in side effects (reactogenicity) experienced by the recipient following coadministration. CDC has provided the details of available information in its guidance on RSV vaccination of older adults: www.cdc.gov/vaccines/vpd/rsv/hcp/older-adults.html#administration-other-vaxs.
CDC advises that when deciding whether to coadminister other vaccines with an RSV vaccine, consider whether the patient is up to date with currently recommended vaccines, the feasibility of the patient returning for additional vaccine doses, their risk for acquiring vaccine-preventable disease, vaccine reactogenicity profiles, and patient preferences.
Last reviewed:
August 11, 2024
Vaccination will have the most benefit if administered in late summer or early fall, just before the RSV season. In most of the continental United States, this corresponds to vaccination during August–October.
If you have an opportunity to vaccinate an eligible patient and are concerned that there will not be an opportunity to vaccinate during an ideal time of year, you may administer RSV vaccine at any time of year. A meaningful degree of protection after vaccination should last at least two years.
Last reviewed:
August 25, 2024
Aim for nirsevimab (Beyfortus, Sanofi) administration in the first week of life for infants born shortly before or during the RSV season (typically October through March). Infants with prolonged birth hospitalizations due to prematurity or other causes should receive nirsevimab shortly before or promptly after discharge.
Infants younger than age 8 months born outside of the RSV season and older infants or toddlers at high risk who are recommended to receive nirsevimab in their second RSV season, should aim to receive nirsevimab shortly before the start of the RSV season (typically October).
If the ideal timing is missed, age-eligible infants and children who have not yet received a dose may be immunized at any time during the RSV season.
If you are located in Alaska, Hawaii, or another region of the United States with a different pattern of RSV circulation, follow the timing guidance of your state or territorial public health officials.
Last reviewed:
August 25, 2024
CDC has published an immunization information statement (IIS) for nirsevimab (Beyfortus, Sanofi) that is the equivalent of the vaccine information statement (VIS) for vaccines. Just as with a VIS, providers should give the IIS to the parent or caregiver before immunization and document it in the medical record.
Access the current nirsevimab IIS and translations in numerous languages from Immunize.org at: www.immunize.org/vaccines/vis/iis-rsv/.
Last reviewed:
August 25, 2024
Yes, you should report administration of nirsevimab (Beyfortus, Sanofi) to your state immunization information system (IIS, or “registry”) as you would report vaccine administration. Contact your state immunization program if you have specific questions about reporting to your state immunization information system.
Last reviewed:
August 25, 2024
It is important that all healthcare providers, both prenatal and pediatric, ensure that maternal RSV vaccination status is clearly documented and communicated. Prenatal care providers and birthing hospitals should ensure maternal RSV vaccination is reported to state immunization information systems (registries) and documented in maternal and newborn health records. It is also important to provide the pregnant person with a personal record of immunization.
Failure to document and communicate maternal RSV vaccination may result in extra work for pediatric offices and families to obtain records or in unnecessary administration of nirsevimab (Beyfortus, Sanofi), at a retail cost of approximately $450 per dose.
RSV vaccination is recommended only once, so the history of RSV vaccination is also important information for future pregnancies when the mother would need to be counseled that RSV vaccination is not an option and the infant should receive nirsevimab after delivery for RSV prevention.
Last reviewed:
August 25, 2024
